<DOC>
	<DOCNO>NCT01224392</DOCNO>
	<brief_summary>The investigator propose randomize non-inferiority trial compare preoperative Fluoro Uracil ( FU ) -based chemoradiotherapy radiotherapy simultaneous integrate boost . In patient T3-4 rectal cancer , latter approach consider preferential regard toxicity cost . The metabolic response tumor , assess 18F-2-Fluoro-2-Deoxyglucose-Positron Emission tomography ( 18F-FDG PET ) PET-CT , use surrogate marker cause specific outcome</brief_summary>
	<brief_title>Simultaneous Integrated Boost Preoperative Radiotherapy Rectum Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>histopathologically confirm rectal adenocarcinoma inferior border within 15 cm anal verge tumor evidence T3 T4 disease Magnetic Resonance Imaging ( MRI ) endoluminal ultrasound unresectable metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 3 patient deemed fit radiotherapy , capecitabine surgery pregnant lactating patient woman child bear potential lack effective contraception patient 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>colorectal neoplasm</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>T3-4 rectal cancer</keyword>
</DOC>